In this interview Robert Nelson, Associate Director of Science and Innovation at Covance (Geneva, Switzerland) discusses the importance of biomarkers in drug development, describing key aspects in the current guidance and key considerations to make in the development and validation process.
Robert discusses the aims of the Science and Innovation group at Covance and how they effectively develop biomarker assays to meet the needs of their clients and sponsors as well as speculating on where this field could be in 5 to 10 years’ time and the impact of future regulations.
Q What is your primary focus at Covance?